Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

Jul 31, 2014

Golgi—A Potential Drug Target for Alzheimer's Disease

In this literature review, the authors show how accumulation of amyloid beta peptides leads to Golgi fragmentation.

Golgi—A Potential Drug Target for Alzheimer's Disease

Golgi fragmentation in AD is caused by phosphorylation of Golgi structural proteins, which is induced by Aβ-triggered cyclin-dependent kinase-5 activation. [© psdesign1 - Fotolia.com]

  • First described in 1906 by Alois Alzheimer, Alzheimer's disease (AD) represents the most common form of dementia today and the sixth leading cause of ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »